After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, RNAC falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Cartesian Therapeutics Inc is $197.63M. A total of 0.14 million shares were traded on the day, compared to an average of 103.25K shares.
In the most recent transaction, CHRISTOPHER M JEWELL bought 26,935 shares of RNAC for 7.15 per share on Nov 19 ’25. In a previous transaction on Apr 10 ’25, SPRINGER TIMOTHY A bought 48,595 shares at 10.47 per share. RNAC shares that Director owns now total 620,175.
Among the insiders who bought shares, SPRINGER TIMOTHY A acquired of 41,782 shares on Apr 09 ’25 at a per-share price of $9.43. This resulted in the Director holding 571,580 shares of RNAC after the transaction. In another insider transaction, SPRINGER TIMOTHY A bought 36,338 shares at $10.77 per share on Apr 11 ’25. Company shares held by the Director now total 656,513.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, RNAC has a high of $26.50 and a low of $5.98.
As of this writing, RNAC has an earnings estimate of -$0.79 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.79 per share and a lower estimate of -$0.79. The company reported an EPS of -$0.59 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. RNAC’s latest balance sheet shows that the firm has $128.06M in Cash & Short Term Investments as of fiscal 2021. There were $35.28M in debt and $72.25M in liabilities at the time. Its Book Value Per Share was -$1.38, while its Total Shareholder’s Equity was $22.52M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNAC is Buy with a score of 4.30.
